Transforming Growth Factor-β and Bone Morphogenetic Protein Signaling Pathways in Pathological Cardiac Hypertrophy

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2024 Jan 5

PMID 38179789

Authors

Jing Wen

Guixiang Liu

Mingjie Liu

Huarui Wang

Yunyan Wan

Zhouhong Yao

Nannan Gao

Yuanyuan Sun

Ling Zhu

Affiliations

Soon will be listed here.

Abstract

Pathological cardiac hypertrophy (referred to as cardiac hypertrophy) is a maladaptive response of the heart to a variety of pathological stimuli, and cardiac hypertrophy is an independent risk factor for heart failure and sudden death. Currently, the treatments for cardiac hypertrophy are limited to improving symptoms and have little effect. Elucidation of the developmental process of cardiac hypertrophy at the molecular level and the identification of new targets for the treatment of cardiac hypertrophy are crucial. In this review, we summarize the research on multiple active substances related to the pathogenesis of cardiac hypertrophy and the signaling pathways involved and focus on the role of transforming growth factor-β (TGF-β) and bone morphogenetic protein (BMP) signaling in the development of cardiac hypertrophy and the identification of potential targets for molecular intervention. We aim to identify important signaling molecules with clinical value and hope to help promote the precise treatment of cardiac hypertrophy and thus improve patient outcomes.

References

Ren J, Fang C . Small guanine nucleotide-binding protein Rho and myocardial function. Acta Pharmacol Sin. 2005; 26(3):279-85. DOI: 10.1111/j.1745-7254.2005.00059.x. View

Meng H, Du Z, Lu W, Wang Q, Sun X, Jiang Y . Baoyuan decoction (BYD) attenuates cardiac hypertrophy through ANKRD1-ERK/GATA4 pathway in heart failure after acute myocardial infarction. Phytomedicine. 2021; 89:153617. DOI: 10.1016/j.phymed.2021.153617. View

Bueno O, Molkentin J . Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res. 2002; 91(9):776-81. DOI: 10.1161/01.res.0000038488.38975.1a. View

Chen Y, Pan R, Zhang J, Liang T, Guo J, Sun T . Pinoresinol diglucoside (PDG) attenuates cardiac hypertrophy via AKT/mTOR/NF-κB signaling in pressure overload-induced rats. J Ethnopharmacol. 2021; 272:113920. DOI: 10.1016/j.jep.2021.113920. View

Lim J, Park S, Hwang H, Park E, Nam J, Kim J . TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation. J Mol Cell Cardiol. 2005; 39(4):627-36. DOI: 10.1016/j.yjmcc.2005.06.016. View

Li H, Huang Y, Zhang C, Liu G, Wei Y, Wang A . Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathways. Free Radic Biol Med. 2006; 40(10):1756-75. DOI: 10.1016/j.freeradbiomed.2006.01.005. View

Pan J, Singh U, Takahashi T, Oka Y, Palm-Leis A, Herbelin B . PKC mediates cyclic stretch-induced cardiac hypertrophy through Rho family GTPases and mitogen-activated protein kinases in cardiomyocytes. J Cell Physiol. 2004; 202(2):536-53. DOI: 10.1002/jcp.20151. View

Derynck R, Zhang Y . Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-84. DOI: 10.1038/nature02006. View

Li F, Xia W, Li A, Zhao C, Sun R . Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats. Chin Med J (Engl). 2007; 120(1):22-9. View

10.

Bisserier M, Berthouze-Duquesnes M, Breckler M, Tortosa F, Fazal L, de Regibus A . Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+/calmodulin-dependent protein kinase II signaling. Circulation. 2014; 131(4):390-400. DOI: 10.1161/CIRCULATIONAHA.114.010686. View

11.

Guo S, Liu Y, Gao L, Xiao F, Shen J, Xing S . TBC1D25 Regulates Cardiac Remodeling Through TAK1 Signaling Pathway. Int J Biol Sci. 2020; 16(8):1335-1348. PMC: 7085222. DOI: 10.7150/ijbs.41130. View

12.

Liou S, Hsu J, Chen Y, Chen I, Yeh J . KMUP-1 Attenuates Endothelin-1-Induced Cardiomyocyte Hypertrophy through Activation of Heme Oxygenase-1 and Suppression of the Akt/GSK-3β, Calcineurin/NFATc4 and RhoA/ROCK Pathways. Molecules. 2015; 20(6):10435-49. PMC: 6272697. DOI: 10.3390/molecules200610435. View

13.

Sun S, Yang S, Zhang N, Yu C, Liu J, Feng W . Astragalus polysaccharides alleviates cardiac hypertrophy in diabetic cardiomyopathy via inhibiting the BMP10-mediated signaling pathway. Phytomedicine. 2023; 109:154543. DOI: 10.1016/j.phymed.2022.154543. View

14.

Yagi S, Aihara K, Ikeda Y, Sumitomo Y, Yoshida S, Ise T . Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res. 2007; 102(1):68-76. DOI: 10.1161/CIRCRESAHA.107.163493. View

15.

Hunter J, Zeidan A, Javadov S, Kilic A, Rajapurohitam V, Karmazyn M . Nitric oxide inhibits endothelin-1-induced neonatal cardiomyocyte hypertrophy via a RhoA-ROCK-dependent pathway. J Mol Cell Cardiol. 2009; 47(6):810-8. DOI: 10.1016/j.yjmcc.2009.09.012. View

16.

Shimoyama M, Hayashi D, Takimoto E, Zou Y, Oka T, Uozumi H . Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation. 1999; 100(24):2449-54. DOI: 10.1161/01.cir.100.24.2449. View

17.

Seksaria S, Mehan S, Dutta B, Gupta G, Ganti S, Singh A . Oxymatrine and insulin resistance: Focusing on mechanistic intricacies involve in diabetes associated cardiomyopathy via SIRT1/AMPK and TGF-β signaling pathway. J Biochem Mol Toxicol. 2023; 37(5):e23330. DOI: 10.1002/jbt.23330. View

18.

Wang M, Zhang W, Zhu J, Fu G, Zhou B . Breviscapine ameliorates hypertrophy of cardiomyocytes induced by high glucose in diabetic rats via the PKC signaling pathway. Acta Pharmacol Sin. 2009; 30(8):1081-91. PMC: 4006682. DOI: 10.1038/aps.2009.95. View

19.

Clemente C, Xavier-Neto J, Dalla Costa A, Consonni S, Antunes J, Rocco S . Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways. J Mol Cell Cardiol. 2011; 52(2):493-501. DOI: 10.1016/j.yjmcc.2011.10.015. View

20.

Braun M, Larosee P, Schon S, Borst M, Strasser R . Differential regulation of cardiac protein kinase C isozyme expression after aortic banding in rat. Cardiovasc Res. 2002; 56(1):52-63. DOI: 10.1016/s0008-6363(02)00511-4. View